Immunological risks of minimization strategies

Transplant International

Volumn 28, Issue 8, 2015, Pages 901-910

  Snanoudj, Renaud ^a   Tinel, Claire ^a   Legendre, Christophe ^a  

^a HÔPITAL NECKER ENFANTS MALADES   (France)

Author keywords

immunosuppression; kidney transplantation; outcome; rejection

Indexed keywords

AZATHIOPRINE; BASILIXIMAB; BELATACEPT; CALCINEURIN INHIBITOR; CYCLOSPORIN; CYCLOSPORIN A; EVEROLIMUS; IMMUNOSUPPRESSIVE AGENT; MAMMALIAN TARGET OF RAPAMYCIN INHIBITOR; MYCOPHENOLATE MOFETIL; MYCOPHENOLIC ACID; STEROID;

ACUTE GRAFT REJECTION; ANTIBODY SPECIFICITY; CLINICAL PROTOCOL; DISEASE ASSOCIATION; DOSE RESPONSE; DRUG EFFICACY; DRUG EXPOSURE; GRAFT FAILURE; GRAFT SURVIVAL; HUMAN; IMMUNOLOGICAL MONITORING; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT; KIDNEY GRAFT REJECTION; LOW DRUG DOSE; MALIGNANT NEOPLASTIC DISEASE; MONOTHERAPY; PRIORITY JOURNAL; PROGNOSIS; REVIEW; RISK REDUCTION; THERAPY DELAY; TREATMENT PLANNING; ADVERSE EFFECTS; COMBINATION DRUG THERAPY; DRUG ADMINISTRATION; DRUG EFFECTS; GRAFT REJECTION; IMMUNOLOGY; KIDNEY TRANSPLANTATION; PROCEDURES;

CALCINEURIN INHIBITORS; DRUG ADMINISTRATION SCHEDULE; DRUG THERAPY, COMBINATION; GRAFT REJECTION; GRAFT SURVIVAL; HUMANS; IMMUNOSUPPRESSION; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION;

EID: 84947047121     PISSN: 09340874     EISSN: 14322277     Source Type: Journal    
DOI: 10.1111/tri.12570     Document Type: Review

References (72)

1. Myers BD, Ross J, Newton L, Luetscher J, Perlroth M,. Cyclosporine-associated chronic nephropathy. N Engl J Med 1984; 311: 699.
2. Sharif A, Shabir S, Chand S, Cockwell P, Ball S, Borrows R,. Meta-analysis of calcineurin-inhibitor-sparing regimens in kidney transplantation. J Am Soc Nephrol 2011; 22: 2107.
3. Asberg A, Midtvedt K, Line PD, et al,. Calcineurin inhibitor avoidance with daclizumab, mycophenolate mofetil, and prednisolone in DR-matched de novo kidney transplant recipients. Transplantation 2006; 82: 62.
4. Gheith OA, Bakr MA, Fouda MA, Shokeir AA, Sobh M, Ghoneim M,. Prospective randomized study of azathioprine vs cyclosporine based therapy in primary haplo-identical living-donor kidney transplantation: 20-year experience. Clin Exp Nephrol 2007; 11: 151.
5. Grimbert P, Baron C, Fruchaud G, et al,. Long-term results of a prospective randomized study comparing two immunosuppressive regimens, one with and one without CsA, in low-risk renal transplant recipients. Transpl Int 2002; 15: 550.
6. Najarian JS, Fryd DS, Strand M, et al,. A single institution, randomized, prospective trial of cyclosporin versus azathioprine-antilymphocyte globulin for immunosuppression in renal allograft recipients. Ann Surg 1985; 201: 142.
7. Cyclosporin a as sole immunosuppressive agent in recipients of kidney allografts from cadaver donors. Preliminary results of a European multicentre trial. Lancet 1982; 2: 57.
8. Ekberg H, Tedesco-Silva H, Demirbas A, et al,. Reduced exposure to calcineurin inhibitors in renal transplantation. N Engl J Med 2007; 357: 2562.
9. Lebranchu Y, Snanoudj R, Toupance O, et al,. Five-year results of a randomized trial comparing de novo sirolimus and cyclosporine in renal transplantation: the SPIESSER study. Am J Transplant 2012; 12: 1801.
10. Pescovitz MD, Vincenti F, Hart M, et al,. Pharmacokinetics, safety, and efficacy of mycophenolate mofetil in combination with sirolimus or ciclosporin in renal transplant patients. Br J Clin Pharmacol 2007; 64: 758.
11. Ekberg H, Bernasconi C, Noldeke J, et al,. Cyclosporine, tacrolimus and sirolimus retain their distinct toxicity profiles despite low doses in the Symphony study. Nephrol Dial Transplant 2010; 25: 2004.
12. Pengel LHM, Liu LQ, Morris PJ,. Do wound complications or lymphoceles occur more often in solid organ transplant recipients on mTOR inhibitors? A systematic review of randomized controlled trials. Transpl Int 2011; 24: 1216.
13. Durrbach A, Rostaing L, Tricot L, et al,. Prospective comparison of the use of sirolimus and cyclosporine in recipients of a kidney from an expanded criteria donor. Transplantation 2008; 85: 486.
14. Kreis H, Cisterne JM, Land W, et al,. Sirolimus in association with mycophenolate mofetil induction for the prevention of acute graft rejection in renal allograft recipients. Transplantation 2000; 69: 1252.
15. Glotz D, Charpentier B, Abramovicz D, et al,. Thymoglobulin induction and sirolimus versus tacrolimus in kidney transplant recipients receiving mycophenolate mofetil and steroids. Transplantation 2010; 89: 1511.
16. Pilat N, Wekerle T,. Belatacept and Tregs: friends or foes? Immunotherapy 2012; 4: 351.
17. Bluestone JA, Liu W, Yabu JM, et al,. The effect of costimulatory and interleukin 2 receptor blockade on regulatory T cells in renal transplantation. Am J Transplant 2008; 8: 2086.
18. Muthukumar T, Dadhania D, Ding R, et al,. Messenger RNA for FOXP3 in the urine of renal-allograft recipients. N Engl J Med 2005; 353: 2342.
19. McHeyzer-Williams M, Okitsu S, Wang N, McHeyzer-Williams L,. Molecular programming of B cell memory. Nat Rev Immunol 2011; 12: 24.
20. Allen CDC, Okada T, Cyster JG,. Germinal-center organization and cellular dynamics. Immunity 2007; 27: 190.
21. Klaus SJ, Pinchuk LM, Ochs HD, et al,. Costimulation through CD28 enhances T cell-dependent B cell activation via CD40-CD40L interaction. J Immunol 1994; 152: 5643.
22. Azuma H, Chandraker A, Nadeau K, et al,. Blockade of T-cell costimulation prevents development of experimental chronic renal allograft rejection. Proc Natl Acad Sci U S A 1996; 93: 12439.
23. Pearson TC, Trambley J, Odom K, et al,. Anti-CD40 therapy extends renal allograft survival in rhesus macaques. Transplantation 2002; 74: 933.
24. Kim EJ, Kwun J, Gibby AC, et al,. Costimulation blockade alters germinal center responses and prevents antibody-mediated rejection: costimulation blockade alters GC response. Am J Transplant 2014; 14: 59.
25. Vincenti F, Larsen C, Durrbach A, et al,. Costimulation blockade with belatacept in renal transplantation. N Engl J Med 2005; 353: 770.
26. Vincenti F, Charpentier B, Vanrenterghem Y, et al,. A phase III study of belatacept-based immunosuppression regimens versus cyclosporine in renal transplant recipients (BENEFIT Study). Am J Transplant 2010; 10: 535.
27. Durrbach A, Pestana JM, Pearson T, et al,. A phase III study of belatacept versus cyclosporine in kidney transplants from extended criteria donors (BENEFIT-EXT Study). Am J Transplant 2010; 10: 547.
28. Vincenti F, Larsen CP, Alberu J, et al,. Three-year outcomes from BENEFIT, a randomized, active-controlled, parallel-group study in adult kidney transplant recipients. Am J Transplant 2012; 12: 210.
29. Medina Pestana JO, Grinyo JM, Vanrenterghem Y, et al,. Three-year outcomes from BENEFIT-EXT: a phase III study of belatacept versus cyclosporine in recipients of extended criteria donor kidneys. Am J Transplant 2012; 12: 630.
30. Vincenti F, Blancho G, Durrbach A, et al,. Five-year safety and efficacy of belatacept in renal transplantation. J Am Soc Nephrol 2010; 21: 1587.
31. Grannas G, Schrem H, Klempnauer J, Lehner F,. Ten years experience with belatacept- based immunosuppression after kidney transplantation. J Clin Med Res 2014; 6: 98.
32. Rostaing L, Vincenti F, Grinyõ J, et al,. Long-term belatacept exposure maintains efficacy and safety at 5 years: results from the long-term extension of the BENEFIT study: BENEFIT long-term extension. Am J Transplant 2013; 13: 2875.
33. Charpentier B, Medina Pestana JO, del C Rial M, et al,. Long-term exposure to belatacept in recipients of extended criteria donor kidneys: BENEFIT-EXT long-term extension. Am J Transplant 2013; 13: 2884.
34. Lefaucheur C, Loupy A, Vernerey D, et al,. Antibody-mediated vascular rejection of kidney allografts: a population-based study. Lancet 2013; 381: 313.
35. Rostaing L, Massari P, Garcia VD, et al,. Switching from Calcineurin inhibitor-based regimens to a belatacept-based regimen in renal transplant recipients: a randomized phase II study. Clin J Am Soc Nephrol 2010; 6: 430.
36. Alemtuzumab-based induction treatment versus basiliximab-based induction treatment in kidney transplantation (the 3C Study): a randomised trial. Lancet 2014; 384: 1684.
37. Ciancio G, Burke GW, Gaynor JJ, et al,. A randomized trial of three renal transplant induction antibodies: early comparison of tacrolimus, mycophenolate mofetil, and steroid dosing, and newer immune-monitoring. Transplantation 2005; 80: 457.
38. Hernández D, Miquel R, Porrini E, et al,. Randomized controlled study comparing reduced calcineurin inhibitors exposure versus standard cyclosporine-based immunosuppression. Transplantation 2007; 84: 706.
39. Heidt S, Roelen DL, Eijsink C, van Kooten C, Claas FHJ, Mulder A,. Effects of immunosuppressive drugs on purified human B cells: evidence supporting the use of MMF and rapamycin. Transplantation 2008; 86: 1292.
40. Haneda M, Owaki M, Kuzuya T, Iwasaki K, Miwa Y, Kobayashi T,. Comparative analysis of drug action on B-cell proliferation and differentiation for mycophenolic acid, everolimus, and prednisolone. Transplantation 2014; 97: 405.
41. Struijk GH, Minnee RC, Koch SD, et al,. Maintenance immunosuppressive therapy with everolimus preserves humoral immune responses. Kidney Int 2010; 78: 934.
42. Lorber MI, Mulgaonkar S, Butt KMH, et al,. Everolimus versus mycophenolate mofetil in the prevention of rejection in de novo renal transplant recipients: a 3-year randomized, multicenter, phase III study. Transplantation 2005; 80: 244.
43. Vítko S, Margreiter R, Weimar W, et al,. Three-year efficacy and safety results from a study of everolimus versus mycophenolate mofetil in de novo renal transplant patients. Am J Transplant 2005; 5: 2521.
44. Vitko S, Tedesco H, Eris J, et al,. Everolimus with optimized cyclosporine dosing in renal transplant recipients: 6-month safety and efficacy results of two randomized studies. Am J Transplant 2004; 4: 626.
45. Tedesco-Silva H, Vitko S, Pascual J, et al,. 12-month safety and efficacy of everolimus with reduced exposure cyclosporine in de novo renal transplant recipients. Transpl Int 2007; 20: 27.
46. Salvadori M, Scolari MP, Bertoni E, et al,. Everolimus with very low-exposure cyclosporine a in de novo kidney transplantation: a multicenter, randomized, controlled trial. Transplantation 2009; 88: 1194.
47. Cibrik D, Silva HT, Vathsala A, et al,. Randomized trial of everolimus-facilitated calcineurin inhibitor minimization over 24 months in renal transplantation. Transplant J 2013; 95: 933.
48. Chan L, Greenstein S, Hardy MA, et al,. Multicenter, randomized study of the use of everolimus with tacrolimus after renal transplantation demonstrates its effectiveness. Transplantation 2008; 85: 821.
49. Langer RM, Hené R, Vitko S, et al,. Everolimus plus early tacrolimus minimization: a phase III, randomized, open-label, multicentre trial in renal transplantation: renal function, efficacy and safety with everolimus + tacrolimus minimization. Transpl Int 2012; 25: 592.
50. Kasiske BL, Heim-Duthoy K, Ma JZ,. Elective cyclosporine withdrawal after renal transplantation. A meta-analysis. JAMA 1993; 269: 395.
51. Kasiske BL, Chakkera HA, Louis TA, Ma JZ,. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000; 11: 1910.
52. Dantal J, Hourmant M, Cantarovich D, et al,. Effect of long-term immunosuppression in kidney-graft recipients on cancer incidence: randomised comparison of two cyclosporin regimens. Lancet 1998; 351: 623.
53. Abramowicz D, Manas D, Lao M, et al,. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen in stable kidney transplant recipients: a randomized, controlled study. Transplantation 2002; 74: 1725.
54. Abramowicz D, Del Carmen Rial M, Vitko S, et al,. Cyclosporine withdrawal from a mycophenolate mofetil-containing immunosuppressive regimen: results of a five-year, prospective, randomized study. J Am Soc Nephrol 2005; 16: 2234.
55. Hazzan M, Labalette M, Copin MC, et al,. Predictive factors of acute rejection after early cyclosporine withdrawal in renal transplant recipients who receive mycophenolate mofetil: results from a prospective, randomized trial. J Am Soc Nephrol 2005; 16: 2509.
56. Hazzan M, Buob D, Labalette M, et al,. Assessment of the risk of chronic allograft dysfunction after renal transplantation in a randomized cyclosporine withdrawal trial. Transplantation 2006; 82: 657.
57. Ekberg H, Grinyõ J, Nashan B, et al,. Cyclosporine sparing with mycophenolate mofetil, daclizumab and corticosteroids in renal allograft recipients: the CAESAR study. Am J Transplant 2007; 7: 560.
58. Dudley C, Pohanka E, Riad H, et al,. Mycophenolate mofetil substitution for cyclosporine a in renal transplant recipients with chronic progressive allograft dysfunction: the "creeping creatinine" study. Transplantation 2005; 79: 466.
59. Suwelack B, Gerhardt U, Hohage H,. Withdrawal of cyclosporine or tacrolimus after addition of mycophenolate mofetil in patients with chronic allograft nephropathy. Am J Transplant 2004; 4: 655.
60. Frimat L, Cassuto-Viguier E, Charpentier B, et al,. Impact of cyclosporine reduction with MMF: a randomized trial in chronic allograft dysfunction. The "reference" study. Am J Transplant 2006; 6: 2725.
61. Frimat L, Cassuto-Viguier E, Provôt F, et al,. Long-term impact of cyclosporin reduction with MMF treatment in chronic allograft dysfunction: reference study 3-year follow up. J Transplant 2010; 2010: 11, Article ID 402750.
62. Michonneau D, Suarez F, Lambert J, et al,. Late-onset post-transplantation lymphoproliferative disorders after kidney transplantation: a monocentric study over three decades. Nephrol Dial Transplant 2013; 28: 471.
63. Serre J-E, Michonneau D, Bachy E, et al,. Maintaining calcineurin inhibition after the diagnosis of post-transplant lymphoproliferative disorder improves renal graft survival. Kidney Int 2014; 85: 182.
64. Lim WH, Eris J, Kanellis J, et al,. A systematic review of conversion from calcineurin inhibitor to Mammalian target of rapamycin inhibitors for maintenance immunosuppression in kidney transplant recipients. Am J Transplant 2014; 14: 2106.
65. Lebranchu Y, Thierry A, Toupance O, et al,. Efficacy on renal function of early conversion from cyclosporine to sirolimus 3 months after renal transplantation: concept study. Am J Transplant 2009; 9: 1115.
66. Budde K, Becker T, Arns W, et al,. Everolimus-based, calcineurin-inhibitor-free regimen in recipients of de-novo kidney transplants: an open-label, randomised, controlled trial. Lancet 2011; 377: 837.
67. Mjörnstedt L, Sørensen SS, von Zur Mühlen B, et al,. Improved renal function after early conversion from a calcineurin inhibitor to everolimus: a randomized trial in kidney transplantation. Am J Transplant 2012; 12: 2744.
68. Liefeldt L, Brakemeier S, Glander P, et al,. Donor-specific HLA antibodies in a cohort comparing everolimus with cyclosporine after kidney transplantation. Am J Transplant 2012; 12: 1192.
69. Hertig A, Kamar N, Albano L, et al,. Epithelial to mesenchymal transition markers in kidney transplant recipients: The CERTITEM Trial. World Transplant Congress San Francisco July 26-31, 2014, Abstract #717.
70. Euvrard S, Morelon E, Rostaing L, et al,. Sirolimus and secondary skin-cancer prevention in kidney transplantation. N Engl J Med 2012; 367: 329.
71. Hoogendijk-van den Akker JM, Harden PN, Hoitsma AJ, et al,. Two-year randomized controlled prospective trial converting treatment of stable renal transplant recipients with cutaneous invasive squamous cell carcinomas to sirolimus. J Clin Oncol 2013; 31: 1317.
72. Campbell SB, Walker R, Tai SS, Jiang Q, Russ GR,. Randomized controlled trial of sirolimus for renal transplant recipients at high risk for nonmelanoma skin cancer. Am J Transplant 2012; 12: 1146.